GlassScriptPhysician profile
Heather Taggart
NPI 1528118528
$2,283.98
in general payments reported to CMS, 2019-2025
31 companies · $401 in 2025
The $401 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $176 · 2021: $178 · 2022: $268 · 2023: $437 · 2024: $528 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $444.11 | 2019-2025 | Liletta, Lo Loestrin Fe, Vraylar |
| Sumitomo Pharma America, INC. | $212.27 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $157.17 | 2019-2025 | |
| Organon LLC | $124.76 | 2023-2025 | Nexplanon |
| Astellas Pharma US INC | $113.70 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $105.11 | 2022-2025 | |
| Exeltis, USA INC. | $102.26 | 2021-2025 | Slynd, Tyblume |
| Intuitive Surgical, INC. | $90.43 | 2024 | |
| Biogen, INC. | $89.21 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $82.52 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $82.09 | 2023-2025 | Invega Sustenna, Spravato |
| Ironshore Pharmaceuticals INC. | $79.55 | 2019 | |
| Myovant Sciences INC. | $74.91 | 2021-2022 | |
| Pfizer INC. | $74.82 | 2022-2024 | |
| Mallinckrodt Enterprises LLC | $69.80 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.81 | 2019-2024 | Xifaxan |
| Novo Nordisk INC | $48.12 | 2021-2022 | |
| Smith+Nephew, INC. | $44.10 | 2025 | Grafix Pl |
| Abbott Laboratories | $37.75 | 2024-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $29.86 | 2022-2023 | Gardasil 9 |
| Amgen INC. | $28.62 | 2021 | |
| Hologic Sales and Service, LLC | $17.59 | 2024 | Fluent Fluid Management System |
| Sun Pharmaceutical Industries INC. | $17.39 | 2024 | |
| Mallinckrodt Hospital Products INC. | $15.34 | 2020 | |
| Genentech USA, INC. | $14.72 | 2020 | |
| Ironwood Pharmaceuticals, INC | $14.68 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.15 | 2024 | |
| Covidien LP | $12.39 | 2019 | |
| Boston Scientific Corporation | $11.96 | 2019 | |
| Roche Diagnostics Corporation | $11.41 | 2019 | |
| Meditrina | $3.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Taggart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.